The strategy leverages ApoE2’s neuroprotective properties, as this isoform reduces AD risk by 50% and facilitates toxic amyloid-beta clearance while delaying disease onset, in contrast to the pathogenic ApoE4 isoform [111]. The gene discussed is APOE; the disease is Alzheimer disease.